Rollover Protocol for Prior SU011248 Protocols

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: November 25, 2008
Last updated: December 13, 2012
Last verified: December 2012

November 25, 2008
December 13, 2012
March 2004
December 2011   (final data collection date for primary outcome measure)
Duration of Treatment [ Time Frame: Baseline up to Day 28 after last dose of study treatment ] [ Designated as safety issue: Yes ]
Continued access to SU011248 [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00798889 on Archive Site
Not Provided
Collection of long term AE profile [ Time Frame: Last patient last visit ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol
Not Provided
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumors
Drug: Sunitinib
Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
Experimental: Sunitinib
Intervention: Drug: Sunitinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prior SU011248 Protocol.
  • Eligible to continue SU011248 treatment.

Exclusion Criteria:

  • Uncontrolled CNS metastasis.
  • Unfit to receive SU011248.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada,   France,   Greece,   Italy,   Netherlands,   Singapore,   Sweden,   Switzerland,   United Kingdom
Not Provided
Study Director: Pfizer Call Center Pfizer
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP